Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
OpenAI Rejects Apple Trade Secret Theft Claims 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Xiaomi Shares Jump on Europe EV Expansion Plan 
France Targets Shein, Temu With Fast-Fashion Fees 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Add as a preferred source on Google
SAN CARLOS, Calif., March 08, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2017 financial and operating results after the close of the U.S. financial markets on Monday, March 12, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1497629. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/qiinketi.
A replay of the call will be available from March 12, 2018 at 7:30 p.m. ET to April 18, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1497629. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
